Wells Fargo’s Scinai Immunotherapeutics SCNI Stock Holding History

Wells Fargo’s Portfolio SCNI Stock Details SCNI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Hold	0	–	-$12	–	7684
2023 Q4	–	Hold	0	–	–	–	7348
2023 Q3	–	Hold	0	–	–	–	7266
2023 Q2	–	Hold	0	–	–	–	7216
2023 Q1	–	Hold	0	–	–	–	7148
2022 Q4	–	Hold	0	–	–	–	6960
2022 Q3	–	Hold	0	–	–	–	7260
2022 Q2	–	Hold	0	–	–	–	7391
2022 Q1	–	Hold	0	–	–	–	7708
2021 Q4	–	Hold	0	–	–	–	7721
2021 Q3	–	Hold	0	–	–	–	6782
2021 Q2	–	Sell	-1	Closed	-$3.11K	–	6724
2021 Q1	$3K	Sell	1 -1	-50%	-$4.37K	﹤0.01%	6594
2020 Q4	$5K	Sell	2 -2	-50%	-$24.2K	﹤0.01%	6150
2020 Q3	$147K	Buy	4 +3	+300%	+$115K	﹤0.01%	5105
2020 Q2	$27K	Hold	1	–	–	﹤0.01%	5636
2020 Q1	$7K	Hold	1	–	–	﹤0.01%	5818
2019 Q4	$8K	Hold	1	–	–	﹤0.01%	5952
2019 Q3	$5K	Hold	1	–	–	﹤0.01%	6067
2019 Q2	$5K	Hold	1	–	–	﹤0.01%	6038
2019 Q1	$5K	Hold	1	–	–	﹤0.01%	5747
2018 Q4	$4K	Hold	1	–	–	﹤0.01%	6110
2018 Q3	$5K	Hold	1	–	–	﹤0.01%	6123
2018 Q2	$6K	Hold	1	–	–	﹤0.01%	6062
2018 Q1	$5K	Hold	1	–	–	﹤0.01%	6066
2017 Q4	$5K	Hold	1	–	–	﹤0.01%	6057
2017 Q3	$7K	Hold	1	–	–	﹤0.01%	5953
2017 Q2	$6K	Buy	+1	New	+$7.36K	﹤0.01%	5885

Other funds holding SCNI

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Credit Agricole Montrouge Cedex, France $49.3B AUM 36.45% 1-Year Est. Return

MSG

Main Street Group Glen Allen, Virginia $429M AUM 34.03% 1-Year Est. Return

APC

Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Wells Fargo's SCNI Position: Q1 2024 in Review

Wells Fargo held its Scinai Immunotherapeutics (SCNI) position steady in Q1 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7684.

Wells Fargo first reported a position in SCNI in Q2 2017 and has held it in 16 quarters since. The position peaked at $147K in Q3 2020. 11 funds tracked by Wall St. Rank hold SCNI as of Q1 2024.

Wells Fargo held 0 shares of Scinai Immunotherapeutics worth $0 as of Q1 2024.
Wells Fargo left its Scinai Immunotherapeutics share count unchanged in Q1 2024.
Scinai Immunotherapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2024, its #7684 holding.
Wells Fargo first reported a position in Scinai Immunotherapeutics in Q2 2017 and has held it in 16 quarters since.
Wells Fargo's Scinai Immunotherapeutics position peaked at $147K in Q3 2020.
11 funds tracked by Wall St. Rank held Scinai Immunotherapeutics as of Q1 2024.

Based on Wells Fargo's 13F filing for Q1 2024, filed 10 May 2024.